{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '7', 'SELECTION OF PATIENTS', '44', '7.1', 'INCLUSION CRITERIA', '44', '7.2', 'EXCLUSION CRITERIA', '45', '7.2.1', 'Exclusion Criteria Related to Study Methodology', '45', '7.2.2', 'Exclusion Criteria Related to the Active Comparator and/or Mandatory Background', 'Therapies', '46', '7.2.3', 'Exclusion Criteria Related to the Current Knowledge of Sanofi Compound', '47', '7.2.4', 'Additional Exclusion Criteria During or at the end of Screening or Run-in phase before', 'randomization', '48', '8', 'STUDY TREATMENTS', '49', '8.1', 'INVESTIGATIONAL MEDICINAL PRODUCT(S)', '49', '8.1.1', 'Dupilumab', '49', '8.1.2', 'Placebo', '49', '8.1.3', 'Preparation of investigational product', '49', '8.1.4', 'Dosing schedule', '49', '8.2', 'NONINVESTIGATIONAL MEDICINAL PRODUCT(S)', '50', '8.2.1', 'Inhaled Corticosteroids and Second Controller Medication', '50', '8.2.2', 'Reliever Medication(s)', '52', '8.3', 'BLINDING PROCEDURES', '53', '8.3.1', 'Methods of blinding', '53', '8.3.2', 'Randomization code breaking during the study', '53', '8.4', 'METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP', '54', '8.5', 'PACKAGING AND LABELING', '55', '8.6', 'STORAGE CONDITIONS AND SHELF LIFE', '55', '8.7', 'RESPONSIBILITIES', '55', '8.7.1', 'Treatment Accountability and Compliance', '56', '8.7.2', 'Return and/or Destruction of Treatments', '56', '8.8', 'CONCOMITANT MEDICATION', '57', '8.8.1', 'Prohibited Concomitant Medication', '57', '8.8.2', 'Permitted Concomitant Medication', '57', '9', 'ASSESSMENT OF INVESTIGATIONAL MEDICINAL PRODUCT', '59', '9.1', 'PRIMARY ENDPOINT', '59', '9.2', 'SECONDARY ENDPOINTS', '59', 'Property of the Sanofi Group - strictly confidential', 'Page 27', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '9.2.1', 'Key Secondary Efficacy Endpoint', '59', '9.2.2', 'Secondary Efficacy Endpoints', '59', '9.2.2.1', 'Disease-specific Efficacy Measures', '60', '9.2.2.2', 'Disease-specific, Daily Efficacy Assessments', '62', '9.2.2.3', 'Health Care Resource Utilization', '63', '9.2.2.4', 'Patient Reported Outcomes, Including Health Related Quality of Life (Secondary', 'Endpoints)', '64', '9.2.3', 'Safety and Tolerability Endpoints', '65', '9.2.3.1', 'Adverse Events', '66', '9.2.3.2', 'Vital Signs', '66', '9.2.3.3', 'ECG Variables', '66', '9.2.3.4', 'Physical Examination', '67', '9.2.3.5', 'Clinical Laboratory Safety Variables', '67', '9.2.3.6', 'Other Safety Laboratory Tests', '68', '9.2.3.7', 'Pregnancy Test', '68', '9.3', 'OTHER SECONDARY ENDPOINTS', '69', '9.3.1', 'Systemic Drug Concentration, Anti-drug Antibodies, and IgG responses to vaccination', 'during drug treatment', '69', '9.3.1.1', 'Systemic Drug Concentration and Anti-drug Antibodies', '69', '9.3.1.2', 'Humoral Immune Response to Vaccines', '70', '9.3.1.3', 'Biomarker endpoints', '71', '9.4', 'EXPLORATORY ENDPOINTS', '71', '9.4.1', 'Exploratory Endpoints', '71', '9.4.2', 'Pharmacodynamics and Phenotyping', '72', '9.4.2.1', 'Serum Biomarkers', '72', '9.4.2.3', 'Patients Requiring a Permanent Step Up in Background Controller Medication After 2 or', 'More Severe Asthma Exacerbation Events.', '73', '9.4.2.4', 'Other Patient Reported Outcomes Including Health Related Quality of Life (Exploratory', 'Endpoints)', '74', '9.6', 'APPROPRIATENESS OF MEASUREMENTS', '75', '10', 'STUDY PROCEDURES', '76', '10.1', 'VISIT SCHEDULE', '77', '10.1.1', 'Screening Period (Week -5 to Week 0, maximum 35 days prior Day 0)', '77', '10.1.2', 'Screening Visit 1 (Week -4 [+ 1 week], or between Day -35 and Day -21)', '78', '10.1.3', 'Randomization Visit 2 (Week 0, Day 1)', '80', '10.1.4', 'Visit 3 (Week 2 [+ 3 days])', '82', '10.1.5', 'Visit 4 (Week 4 [+ 3 days]) and Visit 6 (Week 8 [ 3 days])', '83', '10.1.6', 'Visit 5 (Week 6 [+ 3 days])', '84', 'Property of the Sanofi Group - strictly confidential', 'Page 28', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}